drugset / Trial / NCT02656173

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

NCT02656173

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the study was to investigate the efficacy of mirabegron versus placebo in male patients with OAB symptoms while taking the alpha blocker, tamsulosin, for BPH.

Timeline

Start
2016-01-25
Primary completion
2017-07-21
Completion
2017-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 50 mg Oral
Background Tamsulosin Other / unclassified 0.2 mg Oral

Indications